Cybin (NYSEAMERICAN:CYBN) Stock gains Momentum As Company Gets New Patent Approval
Cybin (NYSEAMERICAN:CYBN) was up 4% on Wednesday on unusual volume after announcing that US regulators have given it a composition of matter patent that covers CYB004. CYB004 is an investigational deuterated dimethyltryptamine compound the company is currently developing. Trading Data On Wednesday, CYBN stock gained 1.92% to $1.06 with more than 1.26 million shares, compared to its average volume of 1.33 million shares. The stock moved within a range of…